While previous scientific session at the American Heart Association (AHA) in 2010 showed that Rivaroxaban (Xarelto, Bayer/Johnson & Johnson) was not superior to Warfarin in preventing stroke and non-central nervous system (CNS) embolism in patients with atrial fibrillation (AF), currently the researchers concluded that this oral anticoagulant really not superior to warfarin on major embolism and stroke prevention for AF patients. However, this drug showed better in patients treated only with the drug in an on-treatment comparison which is significantly showed reduced the risk of stroke and non-CNS embolization 21% compared with warfarin. This conclusion based on ROCKET-AF trial led by Dr. Manesh Patel from Duke Clinical Research Institute, Durham, NC. The trial involved 14,264 patients with nonvalvular atrial fibrillation who were at an increased risk of stroke, such as those with prior … Read entire article »